Mint Tower Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Mint Tower Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,000	Closed	-$3.23M	–	337
2025 Q4	$3.23M	Buy	+150,000	New	+$2.91M	0.37%	46

Other funds holding AVDL

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mint Tower Capital Management's AVDL Position: Q1 2026 in Review

Mint Tower Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 150,000 shares — an estimated $3.23M sold.

Mint Tower Capital Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $3.23M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Mint Tower Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Mint Tower Capital Management sold 150,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.23M.
Mint Tower Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Mint Tower Capital Management's Avadel Pharmaceuticals position peaked at $3.23M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Mint Tower Capital Management's 13F filing for Q1 2026, filed 4 May 2026.